Wealth Enhancement Advisory Services »

Halozyme Therapeutics shares owned by Wealth Enhancement Advisory Services

Quarter-by-quarter ownership of Halozyme Therapeutics shares owned by Wealth Enhancement Advisory Services from 13F filings

Historical chart of Wealth Enhancement Advisory Services investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Wealth Enhancement Advisory Services consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Wealth Enhancement Advisory Services

Quarter filed Position value Share count Share price at filing
2025-09-30 $11k 10k 1.10
2025-06-30 $25k 25k 1.00
2025-03-31 $11k 10k 1.05
2024-12-31 $9.5k 10k 0.95

More positions owned by Wealth Enhancement Advisory Services

Ishares Tr Core S&p500 Etf (IVV)
Ishares Tr Core Us Aggbd Et (AGG)
Microsoft Corporation (MSFT)
Alps Etf Tr Smith Core Plus (SMTH)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Ishares Tr Msci Intl Moment (IMTM)
Amazon (AMZN)
J P Morgan Exchange Traded F Us Momentum (JMOM)
Schwab Strategic Tr Fundamental Intl (FNDF)
Victory Portfolios Ii Usaa Msci Usa Sm (USVM)
American Centy Etf Tr Us Large Cap Vlu (AVLV)
Ishares Tr Msci Usa Min Vol (USMV)
Ishares Tr Us Treas Bd Etf (GOVT)
Invesco Exchange Traded Fd T S&p500 Quality (SPHQ)
Vanguard Index Fds S&p 500 Etf Shs (VOO)

View all positions for Wealth Enhancement Advisory Services

Top funds holding Halozyme Therapeutics

Steelhead Partners
Opti Capital Management
Linden Advisors
Millennium Management
MacKay Shields
DeepCurrents Investment Group
Tenor Capital Management
BlackRock
Lazard Asset Management
M&G
Calamos Advisors
Wellesley Investment Advisors
UBS O'Connor
Jpmorgan Chase & Co
State Street Corporation

View all funds holding Halozyme Therapeutics